[ad_1]
"It is not without reason that discount contracts for vaccines have been abolished despite the two-partner solution," says Zentgraf. In addition, two providers are in vaccines without a guarantee of supply, if one fails, "regardless of the construction of the contract." To ensure supply, according to the BPI, vaccines of all manufacturers must be "available", that is to say paid by sickness funds
"Exactly this" was regulated by the legislator last year in the Law on Strengthening Drug Supplies. This had excluded exclusive discount agreements for vaccines due to latent supply issues. "Obviously, however, the focus is more on relatively low cost savings for statutory health insurance than on optimal patient care," Zentgraf accuses. It is "a significant risk, especially for the next influenza season".
The BPI has long weighed on vaccine reimbursement regulations, most recently against the vaccination agreement between AOK Nordost and Berliner Apotheker-Verein. At the end of March, the conflict even went to court: in a press release, the BPI had strongly criticized the AOK. Among other things, he criticized the fund for "controlling the supply through the back door". With that, she risked "seeing shortages of eye for the patients". In the press release was also explicitly talked about "offer model" and "discount contract".
[ad_2]
Source link
